Crizotinib Medication Guide: Detailed explanation of correct usage and dosage

Crizotinib is a cutting-edge anti-cancer drug that specifically targets advanced or metastatic non-small cell lung cancer (NSCLC) caused by ALK (anaplastic lymphoma kinase) or ROS1 (c-ROS proto-oncogene 1) gene abnormalities. In addition, it is approved for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) and unresectable, relapsed or refractory inflammatory myofibroblastic tumor (IMT). When preparing a patient to start treatment with crizotinib, it is critical to understand the correct usage and dosage.

Crizotinib is available in capsule and granule forms. Capsules should be swallowed whole and avoid chewing, crushing or splitting. If the patient chooses granules, they can pour the granules directly into the mouth, or first pour them into the oral administration aids provided (such as spoons, medicine cups), and then drink enough water immediately to ensure that the medicine is completely swallowed.

For adult patients with ALK- or ROS1-positive NSCLC, the standard dose is 250 mg twice daily. For pediatric and adult patients with relapsed or refractory ALCL, the dose will be based on body surface area and is usually 280 mg/m² twice daily. For unresectable, recurrent or refractory IMT, the adult dose is 250 mg twice daily; the pediatric dose is also based on body surface area. If adverse reactions occur during medication, the doctor may adjust the patient's dose of crizotinib.

Common adjustments include reducing to 200 mg twice daily and then to 250 mg once daily. If the adjusted dose is still not tolerated, the doctor may recommend that the patient temporarily discontinue the medication.

Please note that crizotinib is a powerful drug and must be used exactly as directed by your doctor. During medication, regular monitoring and follow-up are crucial to ensure the effectiveness of the medication and patient safety. If you have any questions or discomfort, please communicate with your doctor in time.